Abionyx Rob Scott nomm directeur mdical et responsable de la RD - Option Finance

ABNX Stock  EUR 1.21  0.03  2.42%   
About 61% of Abionyx Pharma's investor base is looking to short. The analysis of current outlook of investing in Abionyx Pharma SA suggests that many traders are alarmed regarding Abionyx Pharma's prospects. The current market sentiment, together with Abionyx Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Abionyx Pharma SA stock news signals to limit their universe of possible portfolio assets.
  
Abionyx Rob Scott nomm directeur mdical et responsable de la RD Option Finance

Read at news.google.com
Google News at Macroaxis
  

Abionyx Pharma Fundamental Analysis

We analyze Abionyx Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abionyx Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abionyx Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Return On Asset

Return On Asset Comparative Analysis

Abionyx Pharma is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Abionyx Pharma SA Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Abionyx Pharma stock to make a market-neutral strategy. Peer analysis of Abionyx Pharma could also be used in its relative valuation, which is a method of valuing Abionyx Pharma by comparing valuation metrics with similar companies.

Complementary Tools for Abionyx Stock analysis

When running Abionyx Pharma's price analysis, check to measure Abionyx Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abionyx Pharma is operating at the current time. Most of Abionyx Pharma's value examination focuses on studying past and present price action to predict the probability of Abionyx Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abionyx Pharma's price. Additionally, you may evaluate how the addition of Abionyx Pharma to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Money Managers
Screen money managers from public funds and ETFs managed around the world
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Commodity Directory
Find actively traded commodities issued by global exchanges
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities